Royal Bank of Canada’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-3,549
| Closed | -$85K | – | 7975 |
|
|
2023
Q1 | $85K | Sell |
3,549
-9,540
| -73% | -$120K | ﹤0.01% | 5308 |
|
|
2022
Q4 | $139K | Buy |
13,089
+5,320
| +68% | +$42.9K | ﹤0.01% | 5203 |
|
|
2022
Q3 | $35K | Buy |
7,769
+4,854
| +167% | +$22.1K | ﹤0.01% | 5923 |
|
|
2022
Q2 | $11K | Sell |
2,915
-4,149
| -59% | -$19.7K | ﹤0.01% | 6367 |
|
|
2022
Q1 | $51K | Sell |
7,064
-4,895
| -41% | -$29.3K | ﹤0.01% | 6094 |
|
|
2021
Q4 | $67K | Buy |
11,959
+5,215
| +77% | +$33.1K | ﹤0.01% | 6205 |
|
|
2021
Q3 | $43K | Buy |
6,744
+210
| +3% | +$1.35K | ﹤0.01% | 6253 |
|
|
2021
Q2 | $55K | Buy |
6,534
+2,026
| +45% | +$16.3K | ﹤0.01% | 5981 |
|
|
2021
Q1 | $48K | Buy |
4,508
+3,619
| +407% | +$50.9K | ﹤0.01% | 5917 |
|
|
2020
Q4 | $15K | Hold |
889
| – | – | ﹤0.01% | 6208 |
|
|
2020
Q3 | $11K | Sell |
889
-71
| -7% | -$897 | ﹤0.01% | 5904 |
|
|
2020
Q2 | $14K | Buy |
960
+460
| +92% | +$5.81K | ﹤0.01% | 5727 |
|
|
2020
Q1 | $5K | Sell |
500
-450
| -47% | -$5.8K | ﹤0.01% | 6067 |
|
|
2019
Q4 | $14K | Sell |
950
-617
| -39% | -$5.5K | ﹤0.01% | 6031 |
|
|
2019
Q3 | $10K | Buy |
+1,567
| New | +$15.8K | ﹤0.01% | 5794 |
|
Other funds holding PRVB
Royal Bank of Canada's PRVB Position: Q2 2023 in Review
Royal Bank of Canada sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 3,549 shares — an estimated $85K sold.
Royal Bank of Canada first reported a position in PRVB in Q3 2019 and held it in 15 quarters. The position peaked at $139K in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Royal Bank of Canada reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Royal Bank of Canada sold 3,549 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $85K.
- Royal Bank of Canada first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- Royal Bank of Canada's Provention Bio, Inc. Common Stock position peaked at $139K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.